Medicines planning
51 results
Applied filters
New Product Evaluations
22 December 2025A list of new product evaluations that are freely available to NHS staff.
The licence and supporting evidence for denosumab 60mg biosimilars
17 December 2025Denosumab 60mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.
Biosimilar and key generic medicines – December 2025 update
10 December 2025An update about biosimilar and key generic medicines to support system planning and mobilisation.
Preparing to use aflibercept 2mg biosimilar
10 December 2025Aflibercept 2mg biosimilars for use in ophthalmology are expected in December 2025 for NHS use. We offer general information and implementation advice.
The licence and supporting evidence for denosumab 120mg biosimilars
9 December 2025Denosumab 120mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.
Preparing to use denosumab 60mg biosimilar
5 December 2025Biosimilars of denosumab 60mg (Prolia) are expected soon. We offer general information and implementation advice.
New Medicines News
4 December 2025New Medicines News is produced by the SPS Horizon Scanning Service. It highlights recent new product launches and significant medicines regulatory changes.
The licence and supporting evidence for golimumab biosimilar
28 November 2025We highlight evidence for licensed golimumab biosimilar(s) and differences between the biosimilar(s) and the reference product (Simponi).
The licence and supporting evidence for aflibercept biosimilars
28 November 2025Aflibercept 2mg biosimilars Afqlir, Eydenzelt, Yesafili and Vgenfli are expected in December 2025 for NHS use. Learn about supporting evidence and differences.
The licence and supporting evidence for omalizumab biosimilar
14 November 2025We highlight evidence for licensed omalizumab biosimilar(s) and differences between the biosimilar(s) and the reference product (Xolair).